Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
5(83.3%)
Phase 2
1(16.7%)
6Total
Phase 1(5)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT03625453Phase 2Completed

Study of ABX-1431 in Adult Patients With Tourette Syndrome or Chronic Motor Tic Disorder

Role: lead

NCT03447756Phase 1Completed

Titration Study of ABX-1431

Role: lead

NCT03138421Phase 1Completed

Central Pain Study for ABX-1431

Role: lead

NCT02929264Phase 1Completed

An fMRI Study in Healthy Volunteers to Investigate the Effects of ABX-1431 on Experimental Hyperalgesia and Its Neural Correlates

Role: lead

NCT03058562Phase 1Completed

A Study to Evaluate the Effects of ABX-1431 on Patients With Tourette Syndrome

Role: lead

NCT02875678Phase 1Terminated

A Study to Evaluate the Effects of ABX-1431 on Patients With Functional Dyspepsia

Role: lead

All 6 trials loaded